BYM338 vs REGN1033
Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and REGN1033 (Trevogrumab (REGN1033)) — benefits, dosing, side effects, research data, and where to buy.
| Property | BYM338 | REGN1033 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Bimagrumab (BYM338) | Trevogrumab (REGN1033) |
| Molecular Weight | ~148 kDa | ~150 kDa |
| Half-Life | ~2-3 weeks | ~2-3 weeks |
| Amino Acids | N/A | N/A |
| Typical Dose | 10-30 mg/kg IV in trials | 100-300 mg SC or equivalent trial dosing |
| Route | Intravenous | Subcutaneous / Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 60 |
| Research Status | Clinical | Clinical |
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Research Overview
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.